Key result
SGLT2 inhibitors attenuate residual cardiovascular risk in patients with type 2 diabetes by lowering blood pressure through mechanisms including osmotic diuresis, reduced sympathetic tone, and weight loss.
Why the study?
SGLT2 inhibitors are pursued to address residual cardiovascular risk, prompting a review of their mechanisms on blood pressure and cardiorenal protection.
Do SGLT2 inhibitors reduce blood pressure and residual cardiovascular risk in individuals with type 2 diabetes?
Do SGLT2 inhibitors reduce blood pressure and residual cardiovascular risk in individuals with type 2 diabetes?
SGLT2 inhibitors attenuate residual cardiovascular risk in type 2 diabetes partly through blood pressure reduction mediated by osmotic diuresis, sympathetic tone modulation, improved endothelial function, and weight loss.
May support SGLT2 inhibitor consideration for residual CV risk in T2D via BP effects; leaves open dominant mechanisms for prospective trials.
Sodium glucose cotransporter 2 inhibitors (SGLT2) have been increasingly pursued as a promising target for addressing residual cardiovascular risk. Prior trials demonstrated that SGLT2i not only promotes glucose-lowering, but also improves endothelial dysfunction, adiposity, fluid overload, and insulin sensitivity thus contributing to hemodynamic changes implicated in its cardiorenal benefits. The mechanisms in the effect of SGLT2i on blood pressure and their potential role in preventing cardiovascular events are hereby revised.
No takes yet. Share an insight, caveat, or question.
Barreto et al. (2023) conducted a review in Type 2 diabetes. SGLT2 inhibitors was evaluated. SGLT2 inhibitors attenuate residual cardiovascular risk in patients with type 2 diabetes by lowering blood pressure through mechanisms including osmotic diuresis, reduced sympathetic tone, and weight loss.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: